Thus, significantly decreased levels of FL-Gal9 in successfully ATT-treated individuals with EPTB and PTB were observed, suggesting the role of FL-Gal9 as a marker for monitoring response to the treatment of patients with HIV/TB coinfection, irrespective of the site of the infection. The gene discussed is LGALS9; the disease is infection.